Oncology Times
Coverage from 2019 ASCO Annual Meeting
Focus on Multiple Myeloma
Featured Content
Iberdomide in Combo With Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma
The first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase I/II CC-220-MM-001 study were released during an oral presentation at the 2019 ASCO Annual Meeting.
Insights Into Managing Elderly Patients With Multiple Myeloma
Managing elderly patients with multiple myeloma comes with a host of challenges, and insights into caring for this growing population of patients was the focus of an educational session titled “Geriatric Assessment in the Management of Multiple Myeloma” at 2019 ASCO Annual Meeting.
Safety, Efficacy of CC-220
Emory University School of Medicine’s Sagar Lonial, MD, describes a clinical trial involving CC-220 and its potential impact on patient care.
Race & Geographic Location Create Disparities in Multiple Myeloma
Survival rates for multiple myeloma have improved considerably in recent decades thanks to the advent of novel drugs, stem cell transplantation, and management strategies, but this survival gain is not consistent among all patients. Disparities in multiple myeloma care exist, particularly among patients who live in rural areas or who belong to minority populations, and this topic was the focus of an educational session titled “Many Shades of Disparities in Myeloma Care” at the 2019 ASCO Annual Meeting.
Loading